Diseases & Disorders
(G43)
990 on File
NEW YORK CARDIOTHORACIC TRANSPLANT CONSORTIUM INC
Financial strength (30%)
91/100
Reliability (20%)
50/100
Effectiveness (25%)
78/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$251K
Total Revenue
$242K
Total Expenses
$342K
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
91.9%
Fundraising Efficiency
N/A
Operating Reserve
17.00x
Liability-to-Asset
13.7%
Revenue Diversification
51.7%
Compared with Peers
FY 2025
Compared with 693 similar organizations
(United States, Diseases & Disorders, $100K–$1M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
91.9% | 83.5% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
8.1% | 10.0% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
17.0 mo | 11.9 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
13.7% | 0.6% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
51.7% | 93.4% |
P10P90
|
Top quarter |
|
Surplus margin
Surplus as a share of revenue
|
3.8% | 4.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $251K | $242K | $342K | 91.9% | 0 |
| 2023 | $235K | $179K | $301K | 93.0% | 0 |
| 2022 | $202K | $144K | $244K | 93.3% | 0 |
| 2021 | $170K | $132K | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.